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Abstract
Background—We investigated the association between conotruncal heart defects (CTDs) and 
maternal and fetal single nucleotide polymorphisms (SNPs) in 60 genes in the folate, 
homocysteine and pathways. We also investigated whether periconceptional maternal folic acid 
supplementation modified associations between CTDs and SNPs.
Methods—Participants were enrolled in the National Birth Defects Prevention Study between 
1997 and 2007. DNA samples from 616 case-parental triads affected by CTDs and 1,645 control-
parental triads were genotyped using an Illumina® Golden Gate custom SNP panel. A hybrid 
design analysis, optimizing data from case and control trios, was used to identify maternal and 
fetal SNPs associated with CTDs.
Results—Among 921 SNPs, 17 maternal and 17 fetal SNPs had a Bayesian false-discovery 
probability (BFDP) of <0.8. Ten of the 17 maternal SNPs and 2 of the 17 fetal SNPs were found 
within the glutamate-cysteine ligase, catalytic subunit (GCLC) gene. Fetal SNPs with the lowest 
BFDP (rs2612101, rs2847607, rs2847326, rs2847324) were found within the thymidylate 
synthetase (TYMS) gene. Additional analyses indicated that the risk of CTDs associated with 
candidate SNPs was modified by periconceptional folic acid supplementation. Nineteen maternal 
and 9 fetal SNPs had BFDP <0.8 for gene-by-environment (GxE) interactions with maternal folic 
acid supplementation.
Conclusions—These results support previous studies suggesting that maternal and fetal SNPs 
within folate, homocysteine and transsulfuration pathways are associated with CTD risk. Maternal 
use of supplements containing folic acid may modify the impact of SNPs on the developing heart.
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Introduction
Congenital heart defects (CHDs) are the most prevalent structural birth defect, occurring in 
8 to 11 of every 1,000 live births (Botto et al., 2001; Reller et al., 2008). CHDs include a 
broad range of heterogeneous cardiac malformations that may differ in etiology. 
Conotruncal heart defects (CTDs) comprise a subgroup of CHDs that are malformations of 
cardiac outflow tracts and great arteries, including truncus atreriosus, interrupted aortic arch 
type B, transposition of great arteries, double outlet right ventricle, conoventricular septal 
heart defects, tetralogy of Fallot, and pulmonary atresia with ventricular septal defect (Botto 
et al., 2007). These malformations share a common structural origin, being derived from 
cardiac neural crest cells and secondary heart field (Hutson and Kirby, 2007). CTDs account 
for approximately 20% to 30% of all CHDs and occur in 7 per 10,000 live births (Ferencz et 
al., 1985; Kuehl and Loffredo, 2005).
A minority of CTDs are associated with trisomies 13, 18, and 21, 22q11 microdeletion 
syndrome (Ferencz et al., 1985; Theveniau-Ruissy et al., 2008; Lammer et al., 2009), 
maternal diabetes (Ferencz et al., 1990) and obesity (Gilboa et al., 2010) and teratogens such 
as retinoic acid. For the majority of infants diagnosed with a CTD, however, the underlying 
cause remains elusive. Non-syndromic CTDs result from a complex interplay between 
genomic and epigenomic susceptibilities, and parental environmental, lifestyle, and 
endogenous factors (Chowdhury et al., 2012). Identification of genetic risk factors is 
especially challenging because maternal and fetal genetic susceptibilities may affect the 
intrauterine environment and contribute to CTD development (Hobbs et al., 2010; 
Chowdhury et al., 2012). Among first-degree relatives, the recurrence risk ratio of CTD is 
11.7 (95% CI: 8.0, 17.0) (Oyen et al., 2009). It has been suggested that folic acid 
supplementation within the periconceptional period is protective during conotruncal area 
development resulting in reduced risk of conotruncal defects (Botto et al., 2004; Kuehl and 
Loffredo, 2005; Shaw et al., 2005; Goldmuntz et al., 2008). Data from our group and others 
have demonstrated that metabolites in the folate, homocysteine, and transsulfuration 
pathways were altered in women with pregnancies affected by septal, conotruncal and/or 
obstructive CHDs (Kapusta et al., 1999; Hobbs et al., 2005b; Hobbs et al., 2006; Obermann-
Borst et al., 2011).
We hypothesized that common maternal and fetal genetic variants in folate, homocysteine, 
and transsulfuration pathways, which play key roles in one-carbon metabolism and 
glutathione antioxidant defense, are associated with CTDs. We examined the association 
between non-syndromic CTDs and 921 single nucelotide polymorphisms (SNPs) in 60 genes 
involved in three folate-related pathways. The current study represents the most 
comprehensive candidate pathway investigation of common genetic variants and CTDs to 
date.
Materials and Methods
Ethics Statement
The study was approved by University of Arkansas for Medical Sciences’ Institutional 
Review Board and the NBDPS with protocol oversight by the Centers for Disease Control 
Hobbs et al. Page 2
Birth Defects Res A Clin Mol Teratol. Author manuscript; available in PMC 2015 February 18.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
and Prevention (CDC) Center for Birth Defects and Developmental Disabilities. All study 
subjects gave informed written consent. For minors, informed written consent was obtained 
from their legal guardian.
Study population and sample collection
All study subjects were enrolled in the National Birth Defects Research and Prevention 
Study (NBDPS), a multi-site population-based case-control study to investigate the etiology 
of 30 non-syndromic birth defects, creating the largest case-control study of birth defects 
ever conducted in the US. The study population and eligibility criteria for the NBDPS have 
been previously outlined (Yoon et al., 2001). Briefly, subjects were identified through 9 
states’ population-based birth defect surveillance systems. For the current study, cases were 
defined as families who delivered a singleton live birth with a CTD. Cases where the 
pregnancy was affected by a known single gene disorder, chromosomal abnormality, or 
syndrome were excluded. Medical records were abstracted by trained health information 
specialists. All diagnostic tests on cardiac NBDPS case infants were reviewed by a pediatric 
cardiologist to ensure uniform criteria for diagnoses. Diagnostic tests included results from 
echocardiograms, surgical reports, cardiac catherizations, and autopsies. Using a 
classification system developed for NBDPS, which incorporated three dimensions of cardiac 
phenotype, cardiac complexity, and extracardiac anomalies (Botto et al., 2007), we included 
pregnancies that carried offspring diagnosed prenatally or postnatally with conotruncal 
defects as cases. Controls were those born within the same period as cases who had a 
singleton live birth without birth defects, participated in the NBDPS, and were randomly 
selected from birth certificate data or hospital discharge logs. Case and control mothers 
spoke either English or Spanish. Case and control mothers completed a computer-assisted 
telephone interview in which they were asked if they took folic acid containing single or 
multi-vitamins during three months prior to pregnancy and each month during pregnancy. 
All study participants for this analysis submitted buccal cells collected using cytobrushes 
from which DNA was isolated. For the current study, we included NBDPS participants with 
estimated dates of delivery between October 1997 and August 2008.
Folic Acid Supplementation
The mothers were considered to be fully exposed to folic acid containing supplement if they 
reported use of folic acid supplement one month prior to pregnancy and two months after 
pregnancy. The mothers were considered to be partially exposed if they reported use of folic 
acid supplement either one month prior to pregnancy or any of the two months after 
pregnancy. We defined the folic acid supplement users to be the families with the mothers 
either fully or partially exposed to the folic acid supplement.
Collection of DNA from buccal cell samples
NBDPS methods for biologic sample collection and processing are well established 
(Rasmussen et al., 2002). Upon interview completion, the mother receives a sample 
collection kit including cytobrushes to collect buccal (cheek) cell samples from mothers, 
infants and fathers by mail or courier. Each family returns the cytobrushes to study 
laboratories in mailed envelopes. Each collection tube is bar code labeled with an individual 
identifier clearly labeled as MOTHER, FATHER, or INFANT. The CDC laboratory logs 
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and tracks all samples and stores extracted DNA at the CDC storage facility (CDC and 
ATSDR Specimen Packaging, Inventory, and Repository).
Selection of candidate genes and SNPs
Candidate gene selection
Sixty-two candidate genes that encode an enzyme in one of three candidate metabolic 
pathways were selected. Using data from the International HapMap Project, we selected a 
maximally informative set of haplotype tagging SNPs (htSNPs) for each of the selected 62 
candidate genes using an algorithm based on the linkage disequilibrium statistic r2 (Carlson 
et al., 2004). For each gene, htSNPs were chosen from the entire gene region (including 
introns) with additional 10-kb flanking sequences. To choose htSNPs, pairwise r2 values 
were computed for each marker combination within 200 kb for loci with a minor allele 
frequency (MAF) >0.10 in each population studied (Chowdhury et al., 2012). In 
collaboration with Illumina®, htSNPs were chosen based on an Illumina® assay design 
score. The overall score ranges from 0–1 and is based on the predicted optimal 
oligonucleotide probe sequences for each marker. A set of 1536 htSNPs were selected for 
inclusion in a customized Illumina® GoldenGate™ genotyping panel (Illumina®, http://
www.illumina.com).
In 2005–2006, during the design phase of our custom candidate gene panel, there were two 
genes called RFC-1 in commonly used publicly available genetic databases. It was our intent 
to include SNPs from the Reduced folate carrier-1 gene (RFC-1, now called SLC19A1). 
However, after the panel was finalized and in production at Illumina, we discovered that the 
RFC-1 SNPs included in the panel were within the Replication factor C (activator 1) 1 
(RFC-1) gene. This gene is an activator of DNA polymerase and is required for DNA 
synthesis and repair. Thus, the RFC-1 genotype data presented in this report are for SNPs in 
the Replication factor C (activator 1) 1 gene (RFC-1). To validate the identity of each gene, 
a search was performed within the National Center for Bioinformatics databases (Benson et 
al., 2011).
DNA extraction and quantification
DNA was extracted from buccal cell samples using Puregene® DNA purification reagents 
(Qiagen®, Valencia, CA) according to the manufacturer’s protocol. Genomic DNA was 
quantified using ABI™ (Applied Biosystems, Foster City, CA) TaqMan® RNaseP Detection 
Reagents using a standard curve of genomic DNA of known concentration. The standard 
curve samples and the genomic DNA samples from case and control subjects were subjected 
to an initial denaturation at 95°C for 10 min, 40 cycles of polymerase chain reaction (PCR) 
at 95°C for 15 sec, and 60°C for 1 min in an ABI™ PRISM® 7900HT real-time PCR 
instrument. DNA concentrations were calculated from the standard curve using ABI™ 
software.
Whole genome amplification
Genomic DNA (10–15 ng) was used as a template for whole genome amplification (WGA) 
using the GenomePlex® WGA kit according to the manufacturer’s protocol (Sigma, St. 
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Louis, MO). The resultant WGA product was quantified as above, and 200 ng were used for 
genotyping in the Illumina® Golden Gate™ assay. The robustness of whole genome 
amplified DNA in microarray platforms has been previously demonstrated (Cunningham et 
al., 2008).
Genotyping by Illumina® Golden Gate™ Assay
SNP genotyping was conducted using 200 ng (40 ng/μL) of study subject WGA amplified 
DNA using Illumina’s® Golden Gate™ platform (Fan et al., 2003; Fan et al., 2006). 
Genotype analysis was performed according to Golden Gate™ assay’s protocol. BeadChips 
were scanned on Illumina’s® BeadArray™ Reader, and initial genotype calls were generated 
using GenCall, Illumina’s genotyping algorithm.
We found that the quality of genotype clustering varied substantially from SNP to SNP, 
which we attribute to the in silico design of the custom SNP panel without the subsequent 
quality checks that would be applied to a standard commercial SNP panel. The initial 
genotype calls along with the raw intensity data were used as inputs to SNPMClust, a 
bivariate Gaussian model-based genotype clustering and calling algorithm developed in-
house, currently available as an R package on the Comprehensive R Archive Network 
(CRAN; http://cran.r-project.org/) (Chowdhury et al., 2012). After running SNPMClust, 
clustering and classification plots for all SNPs were visually inspected, leading to dropping a 
SNP from analysis or running SNPMClust under non-default settings in some cases.
A subset of Arkansas residents who completed the NBDPS was also recruited for a different 
study at Arkansas Children’s Hospital Research Institute (Hobbs et al., 2005a) and provided 
both blood and buccal samples. Ninety-six participants, for whom both blood and buccal 
samples were available, comprised a pilot study to validate the use of WGA-buccal DNA on 
the custom genotyping platform. As expected, the blood-derived DNA samples, which had 
not undergone WGA, performed better than the WGA product. Out of 1,536 SNPs, 60 SNPs 
exhibited poor clustering behavior even within the blood DNA samples and were dropped 
from subsequent analysis. Among 94 participants for whom both DNA samples produced 
high call rates, and for those genotype calls in which both the blood and WGA-buccal 
samples passed the quality control steps described below, the concordance rate averaged 
99.2%. We therefore have confidence in the fidelity of genotypes based on WGA-buccal 
DNA when appropriate standards are applied.
Statistical Methods
Post-genotyping Quality Control
We removed 297 individuals because they had either high no-call rates, or high rates of 
Mendelian inconsistency. We further applied stringent quality control measures to ensure 
high-quality genotypes, excluding SNPs with no-call rates > 10% (328 SNPs), Mendelian 
error rates > 5% (11 SNPs), MAF < 5% (204 SNPs), or significant deviation from Hardy-
Weinberg Equilibrium in at least one racial group (p < 10−4, 12 SNPs). The final dataset 
included 4,648 individuals (94%), each with 921 SNPs (60% of the original set of SNPs, 
representing 60 candidate genes), including 230 case triads, 222 case dyads, 96 case 
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mothers, 31 case fathers, 37 case infants, 559 control triads, 587 control dyads, 242 control 
mothers, 94 control fathers, and 163 control infants.
Statistical Analyses
Because the NBDPS enrolled case- and control-parental trios, we employed a hybrid log-
linear model approach as suggested by Weinberg and Umbach (Weinberg and Umbach, 
2005) to optimize the power of this study design. This hybrid approach uses data from both 
case- and control families to estimate the genetic relative risk due to maternal and fetal 
genotypes. We also extended this model to explore the interaction between SNPs in our 
candidate regions and periconceptional folic acid supplementation.
Briefly, the Weinberg/Umbach log-linear approach simultaneously estimates the 
contributions of maternal and fetal genotypes for a given SNP by fitting the following 
model:
[1]
where μj, j = 1, …, 6 correspond to the six possible parental mating type categories assuming 
mating symmetry. The indicator variable I(D=1) equals 1 for case families (I(D=1) = 1) and 0 
for control families; IM is an indicator for maternal genetic effects and equals the number of 
copies of the variant allele (0, 1, or 2) carried by the mother; and IC is the corresponding 
indicator for fetal genetic effects. By defining the indicators for maternal and fetal genetic 
effects in this way, we implicitly assume multiplicative (i.e. log-additive) risk per allele. An 
expectation-maximization (EM) algorithm is used to estimate the relative risk in the 
presence of incomplete data.
We hypothesized that genetic effects on CTD risk might be modulated by maternal folic 
acid supplements use periconceptionally. We therefore extended the log-linear approach to 
estimate G×E interactive effects for each SNP, where periconceptional folic acid 
supplementation is defined as the environmental exposure of interest. For each SNP, the 
following model was fitted:
[2]
where μj, I(D=1), IM, and IC are defined as above, while δk, k= 1, …, 6 are the stratum 
parameters for six mating types for exposed families, and I(E=1) is the indicator for exposed 
families (I(E=1) = 1) and unexposed families (I(E=1) = 0). Based on this extended log-linear 
model, maternal and fetal GxE interactions can be evaluated by using a Wald test for the 
parameters β3 and β4, respectively.
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Then the relative risk for maternal genetic effect among unexposed families can be 
estimated by exp (β̂1) with the estimated standard error for β̂1 being . The relative 
risk for maternal genetic effect among exposed families can be estimated by exp (β̂1 + β̂3), 
and the standard error for β̂1 + β̂3 can be estimated by . The relative 
risk for fetal genetic effect among unexposed and exposed families were estimated 
accordingly.
Bayesian false-discovery probability
The Bayesian false-discovery probability (BFDP) computed using results from log-linear 
models was considered an appropriate approach in this candidate gene study (Wakefield, 
2007; Liu et al., 2010; Oh et al., 2010; Park et al., 2010; Spitz et al., 2012; Zienolddiny et 
al., 2013). For a specific SNP-disease association, BFDP is defined as the probability of that 
association being null (i.e. a false discovery), conditional on the observed data. The BFDP 
threshold was pre-set at 0.8; in decision theoretic terms, this threshold implies that a false 
nondiscovery is considered four times as costly as a false discovery. The prior probability of 
disease association for each candidate SNP was set at 0.05, and the prior distribution on 
effect size, given a true association, was a beta distribution scaled such that an odds ratio of 
1.5 was the 97.5th percentile of the prior.
Software used for data analysis included SAS 9.3 (SAS Institute Inc., Cary, NC), R 2.15.0 
(R Development Core Team, Vienna, Austria), LEM program (Vermunt, 1997), and 
HAPLOVIEW 4.2 (Barrett et al., 2005).
Results
There were a total of 2,261 families in the analytic sample including 616 case-families and 
1,645 control-families. Of the 616 cases, 272 (44.2%) had tetralogy of Fallot, 252 (40.0%) 
had D-transposition of great arteries, 25 (4.1%) had double outlet right ventricle, 37 (6.0%) 
had conoventricular septal defects, 23 (3.7%) had truncus atreriosus, and 7 (1.1%) had 
interrupted aortic arch type B.
Maternal characteristics for case and control families are summarized in Table 1. Among 
women included in the analysis, the majority were non-Hispanic white (66% of cases and 
69% of controls), with some college education (59% cases and 62% controls) and a normal 
BMI (50% cases and 55% controls). Distributions of maternal education level, body mass 
index, household income, and maternal use of alcohol, tobacco or multivitamins containing 
folic acid during the first trimester were similar between cases and controls. No statistically 
significant differences were found between case and control mothers except for age at 
delivery, 27.5 years, and 28.3 years, respectively.
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CTDs and SNP Associations
Using a hybrid study design combining data from case- and control-parent trios, we 
estimated associations between conotruncal heart defects and each of the 921 SNPs. In 
analyses including only case-parental trios, untransmitted alleles from either parents provide 
allelic controls. In the hybrid analyses, alleles of case infants are compared with alleles of 
control infants providing additional statistical power (Skare et al., 2012). In the hybrid 
model, separate relative risks for maternal and fetal effects are estimated simultaneously in a 
joint model, adjusted for each other. As summarized in Table 2 and displayed in Manhattan 
Plot in Figure 1a, the most significant maternal SNPs were found in the glutamate-cysteine 
ligase, catalytic subunit (GCLC) gene. Specificially, 10 of 17 SNPs with a Bayesian False 
Discovery Probablitity (BFDP) of ≤0.80 were within the GCLC gene. Two fetal SNPs in the 
GCLC gene (rs10948751, rs7742367) were also significant. Of the GCLC SNPs, associated 
with CTD, several were in linkage disequilibrium with each other. Because many are in 
strong linkage disequilibrium they may not function independently and may tag a single 
causal variant or region. The remaining 7 maternal SNPs with a BFDP <0.8, were found in 
the methenlytetrahydrofolate synthetase (MTHFS), superoxide dismutase 2, mitochondrial 
(SOD2), methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR), 
glutaredoxin (thioltransferase) (GLRX), and betaine-homocysteine s-methyltransferase 
(BHMT) genes. Similarly, among 921 fetal SNPs evaluated and displayed in the Manhattan 
Plot in Figure 1b, the most significant fetal SNPs were found in the thymidylate synthetase 
(TYMS) gene. The remaining 11 fetal SNPs that had a Bayesian False Discovery Probability 
of ≤ 0.8 were found in 7 genes: gluthatione peroxidase 4 (GPX4), glutathione S-transferase 
mu 4 (GSTM4), catalase (CAT), O-6-methylguanine-DNA methyltransferase (MGMT), 
microsomal glutathione S-transferase 1 (MGST1), adenosylhomocysteinase-like 2 
(KIAA0828), transcobalamin II (TCN2).
Folic acid supplementation
Maternal use of folic acid containing supplements may interact with either maternal or fetal 
SNPs, or both, to alter the estimated risk of CTDs. The use of folic acid containing 
supplements varied significantly by ethnicity with 63% (n=726) of non-Hispanic white 
control women reporting use compared to 20% (n=30) of African-Americans control and 
33% (n=94) of Hispanic control women. Given the distribution of folic acid supplement use 
among individual race/ethnicity groups and the lower numbers of African-American and 
Hispanic women, analyses to identify folic acid-SNP interactions were restricted to non-
Hispanic whites.
In Table 3, we present maternal (top panel) and fetal (bottom panel) SNPs that demonstrated 
significant (BFDP ≤ 0.8) interactions with maternal use of folic acid supplements. Four of 
the 19 maternal interactions and 6 of the 9 fetal interactions, included SNPs within 
Replication factor C (activator 1) 1 (RFC-1) gene. Furthermore, those SNPs resulting in the 
lowest BFDP, were within the RFC-1 gene. Other maternal genes that included SNPs 
associated with CTDs among women who did not take folic acid supplements included the 
following: nitric oxide synthase 2, inducible (NOS2A), glutathione-dependent prostaglandin 
D synthase (PGDS), O-6 methylguanine-DNA methyltransferase (MGMT), and betaine-
homocysteine methyltransferase (BHMT2 and BHMT). In addition to RFC-1, fetal genes that 
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included SNPs associated with CTDs among women who were not supplement users were 
methenyltetrahydrofolate synthetase (MTHFS), and cystathionine-beta-synthase (CBS).
Discussion
In this population-based, case-control study, we evaluated the association between CTD risk 
and 921 SNPs in 60 genes in candidate pathways. To our knowledge, our study is the most 
comprehensive genotyping effort of common folate-related genetic variants and CTDs. We 
discovered multiple SNPs in fetal and maternal genes that were associated with CTD risk 
independent of folic acid supplement use, and some SNPs that were only associated with 
CTD risk when supplement use was considered.
Maternal genetic variants
The maternal SNP with the smallest BFDP (BFDP=0.15) was in the glutathione-cytosine 
ligase, catalytic subunit (GCLC) gene (rs572494). Twelve different SNPs in the GCLC gene 
were among the 34 maternal and fetal SNPs that had a BFDP ≤ 0.8. GCLC is the rate 
limiting step in glutathione synthesis and is dependent on cellular availability of cysteine. 
The association of SNPs in the GCLC gene with the risk of CTD in infants suggests that 
oxidative stress may be associated with CTD risk. Cellular glutathione protects developing 
embryos from harmful xenobiotics and environmental exposures (Hansen et al., 2004) 
creating an optimal environment for the developing embryo, and oxidative stress has been 
implicated in teratogenesis (Wells et al., 2009).
Fetal genetic variants
Among the 17 fetal SNPs with a BFDP ≤ 0.80, the SNP with the smallest BFDP was within 
the thymidylate synthatase (TYMS; rs2612101) gene and 3 other SNPs in the TYMS gene 
were of importance. TYMS catalyzes the methylation of deoxyuridylate to deoxythymidylate 
using 5,10-methylenetetrahydrofolate as a cofactor (Gibson et al., 2011). By maintaining the 
dTMP pool critical for DNA replication and repair, TYMS is essential in actively dividing 
cells of the embryo (Du et al., 2006). It is plausible that SNPs in TYMS are critical to 
maintainance of metabolic requirements for cell proliferation and growth and essential to 
embryonic development of heart and other structures.
A recent study (Shaw et al., 2009) to determine the associating between CTDs and spina 
bifida, and 118 SNPs in 14 candidate genes included SNPs in the MTHFD2 and TYMS 
genes. Statistically significant associations were observed for SNPs within the MTHFD2 
(rs702465, rs7571842) and TYMS (rs2847159, rs1001761, rs502396) genes for spina bifida, 
but no statistically significant associations were observed for CTDs and the 118 SNPs. Zhu 
and colleagues investigated whether two CTD were associated with two TYMS functional 
variants (rs4544694: a variable number of tandem repeats polymorphism; rs16430: a 6 base-
pair deletion) (Zhu et al., 2012). The investigators did not find a gene-only effect of either 
variant. However, among women who had low folate during the peri-conceptional period, 
they observed a 3.6 fold increase in CTD risk among infants who were homozygous for the 
6 base-pair insertion.
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The RFC-1 gene, Replication factor C (activator 1) 1, encodes the large subunit of 
replication factor 3. Replication factor 3 acts as a DNA–dependent ATPase consisting of 
five subunits and is required for eukaryotic DNA replication and repair (Overmeer et al., 
2010). The RFC-1 gene product is required for activation of DNA polymerase and functions 
by binding to the primer-template junction and with PCNA, and is required for elongation of 
primed DNA templates by DNA polymerase delta and epsilon (Ellison and Stillman, 1998). 
Our observation of an association between CTD risk and multiple maternal and fetal SNPs 
in RFC-1 in women who did not use folic acid supplements suggests that the impact on the 
developing heart of genetic variants in RFC-1 gene, a gene active in DNA synthesis and 
repair, may be modified by maternal folic acid intake. This hypothesis will be a subject for 
further research.
Our study is limited by the inclusion of only common variants that have a minor allele 
frequency >5%. The release of Phase III data from the International HapMap Project and 
data from the 1000 Genomes Project will allow future studies to examine the impact of less 
common variants (Altshuler et al., 2010; Consortium, 2010). Nonsyndromic CTDs have a 
complex etiology and developmental mechanisms that likely includes many gene-gene and 
gene-environment interactions. Investigation of these interactions was beyond the scope of 
the current study, but is planned for future analyses. Future genetic epidemiologic studies 
are needed to replicate our findings. Future studies are needed to more precisely delineate 
the role of MTHFD2 in the developing heart. Deep exome sequencing studies will be 
necessary to discover the functional SNP(s) responsible for changes in enzyme activity that 
may increase embryo susceptibility to development of heart defects.
Future efforts will allow for more indepth analyses of genomic regions our study identified. 
Other studies will be needed to replicate results to gain additional confidence in our 
findings.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1. 
Manhattan Plot: Maternal and infant folate-related SNPs as predictors of CTD risk. The red 
diamonds indicate SNPs that reached BFDP significance threshold.
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FIGURE 2. 
Plot of BFDP significant SNPs on maternal and infant RFC1 for Caucasian mother families: 
both maternal and offspring RFC1 has significant interactive effect with folic acid; SNPs are 
ordered by their physical locations on the gene.
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Table 1
Maternal characteristics for 616 case mothers and 1,645 control mothers
Control (N=1,645) Case (N=616)
Age at delivery, mean (SD) 27.5 (6.0) 28.3 (6.1)
Mother’s race
 African American 143 (9%) 49 (8%)
 Caucasian 1,136 (69%) 401 (66%)
 Hispanic 285 (17%) 123 (20%)
 Others 78 (5%) 39 (6%)
 Missing information 3 4
Mother’s education, N (%)
 <12 years 217 (13%) 83 (14%)
 High school degree or equivalent 413 (25%) 167 (27%)
 1–3 years of college 454 (28%) 173 (28%)
 At least 4 years of college or Bachelor degree 559 (34%) 190 (31%)
 Missing information 2 3
Household income, N (%)
 Less than 10 Thousand 236 (15%) 94 (16%)
 10 to 30 Thousand 408 (27%) 150 (26%)
 30 to 50 Thousand Dollars 348 (23%) 118 (20%)
 More than 50 Thousand 538 (35%) 217 (37%)
 Missing information 115 37
Folic acid supplementation, N (%)
 Unexposed 738 (45%) 299 (49%)
 Partially exposed 359 (22%) 117 (19%)
 Fully Exposed 548 (33%) 197 (32%)
 Missing information 0 3
Alcohol consumption, N (%)
 Unexposed 1,251 (76%) 460 (76%)
 Exposed* 390 (24%) 149 (24%)
 Missing information 4 7
Cigarette smoking, N (%)
 Unexposed 1,356 (82%) 498 (81%)
 Exposed* 288 (18%) 114 (19%)
 Missing information 1 4
Maternal BMI**, N (%)
 Underweight (BMI <18.5) 74 (5%) 31 (5%)
 Normal weight (18.5 <=BMI <25) 880 (55%) 298 (50%)
 Overweight (25 <=BMI <30) 360 (23%) 141 (24%)
 Obese (>=30) 281 (18%) 121 (20%)
 Missing information 50 25
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*
Exposed drinking and smoking were defined as mothers who drank or smoked in any of the 3 months after conception
**
Maternal BMI analytic categories used as defined by the National Heart, Lung, and Blood Institute and the World Health Organization
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